Key facts
- This page summarizes John P. Schmid's Form 4 filing for BlossomHill Therapeutics, Inc. (BLSM).
- 1 reported transaction and 0 derivative rows are listed below.
- Accepted by SEC: 10 Aug 2026, 18:35.
John P. Schmid - 10 Aug 2026 Form 4 Insider Report for BlossomHill Therapeutics, Inc. (BLSM)
- Reporting relationship
- Director
- Issuer ticker
- BLSM
- Reported as of
- 10 Aug 2026
- Net transaction value
- $0
- SEC form
- 4
- Accepted by SEC
- 10 Aug 2026, 18:35:10 UTC
- Prior SEC filing
- 06 Aug 2026
- Source filing
- View source filing
- Reporting owner signature
- /s/ Vincent Liptak, Attorney-in-Fact
Source evidence
Original filing metadata and source links for verification.
4 source fields
Reporting owner
1 detail
Key filing fact
John P. Schmid filed Form 4 for BlossomHill Therapeutics, Inc. (BLSM) on 10 Aug 2026.
Change
- Previous filing in this sequence was filed on 06 Aug 2026.
- Current net transaction value: $0.
Research use
- This tells you what this filing adds before you inspect full transaction and derivative tables.
- You can trace every row back to the original SEC filing document.
Evidence
Filed on Form 4
View source filing
Ownership activity is grounded in SEC Form 4 disclosures.
Reporting Owners (1)
CIK 0001478916
Primary reporting owner
Schmid John P.
- Relationship
- Director
- Address
- C/O BLOSSOMHILL THERAPEUTICS, INC., 10255 SCIENCE CENTER DRIVE, SUITE 200, SAN DIEGO
- Signature
- /s/ Vincent Liptak, Attorney-in-Fact
- Signature date
- 10 Aug 2026
Reported non-derivative transactions
Shares, units, or other non-derivative securities reported in this filing.
BLSM
transaction
Common Stock
Purchase
- Transaction value
- Shares
- +6,000
- Change %
- Price
- $16.00*
- Shares after
- 6,000
- Date
- 10 Aug 2026
- Ownership
- Direct
* marks a reported price that did not pass the local price check.